Skip to main content

What Role Do Nondihydropyridines Have in Patients With CKD?

Roughly 50%-75% of patients with chronic kidney disease (CKD) have high blood pressure. Therefore, it is important to know which antihypertensive interventions are associated with positive outcomes in these patients.[1,2] The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI™) practice guidelines address the pharmacotherapeutic management of this patient population, compiling the subanalyses of trials that focused on the use of antihypertensive agents in patients with CKD.[2-5]
In the setting of arrhythmias, angina, and high-risk cardiovascular disease (CVD), nondihydropyridine (non-DHP) calcium channel blockers (eg, diltiazem and verapamil) are the preferred antihypertensive agents.[2] Because all patients with CKD are classified as being at high risk for CVD, non-DHP calcium channel blockers are indicated along with other antihypertensives.[2] Non-DHPs have shown significant reductions in albuminuria, both alone and in combination with agents that act on the renin-angiotensin system (eg, angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers), as well as reductions in blood pressure.[6-12] However, because there is strong evidence to support the use of both diuretics and renin-angiotensin system blockers in CKD, the use of non-DHP antihypertensives is limited to patients who require additional blood pressure lowering or cannot take or titrate the preferred agents.[1,13-15]
Beyond their efficacy, use of non-DHP calcium channel blockers is often limited by intolerable adverse effects and potential drug/drug interactions.[16] First, the clinician should confirm that all appropriate nonpharmacologic CVD prevention strategies have been implemented. If preferred pharmacologic agents for CVD prevention are not appropriate for use, the clinician should consider use of a non-DHP antihypertensive in patients with CKD to reduce risk for CVD and decrease albuminuria.
Patients who have had renal transplant present an additional set of issues. Small studies have shown the efficacy of non-DHP calcium channel blockers with respect to blood pressure reduction. Moreover, these agents do not kinetically pose an additional toxic threat to the kidney tissue.[17] Similar to CKD, the benefit of using a non-DHP antihypertensive would be most evident in patients with increased proteinuria after transplant.[5,17] However, excretion of immunosuppressant drugs may be diminished, warranting initiation at the lowest possible starting dose. Still, dihydropyridine (DHP) calcium channel blockers (eg, amlodipine and nifedipine) are efficacious and safe and continue to be widely used as post-transplant antihypertensives.[5]
In addition, DHP and non-DHP calcium channel blockers may have beneficial effects, such as allowing use of lower doses of cyclosporine; having fewer associated side effects; and dilating the afferent arteriole, which is often constricted as a side effect of antirejection medications.[5,17-21] Of note, the KDOQI guidelines specifically do not list any single antihypertensive as preferred for post-transplant patients.[5] As in CKD, use of non-DHP calcium channel blockers should be limited to patients who require additional blood pressure lowering or have contraindications to favored therapies.
In summary, non-DHP calcium channel blockers certainly have a role for treatment of hypertension in patients with CKD and patients who have had renal transplant. Specifically, clinicians should use non-DHP antihypertensives as indicated by the NKF-KDOQI guidelines when other preferred pharmacotherapy options are no longer effective or these agents are not tolerated by the patient.
The author wishes to acknowledge the assistance of Joseph P. Falinski, PharmD and Christine Chim, PharmD, PGY1 Residents, and Michael P. Conley, PharmD, and Nga T. Pham, PharmD, AE-C, Assistant Clinical Professors at Northeastern University -- School of Pharmacy and Harbor Health Services, Inc., Boston, Massachusetts.

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Fake drugs given to NHS patients still untraced

Only eight people out of several thousand who received counterfeit drugs from the NHS in an incident in 2007 have been identified. Of those eight, only three have been informed about the incident, a BBC investigation has learned. 72,000 packs of counterfeit drugs entered the UK supply chain in 2007 but 25,000 remain untraced. The regulator, the MHRA, has said it took swift action in 2007 and issued its "most serious recall notice". A new EU directive will further improve patient safety, it added. In the spring of 2007, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an emergency recall of drugs which had been identified as counterfeit. Those recalled included batches of the prostate cancer drug Casodex; of a drug used to treat heart complaints called Plavix; and of Zyprexa, which is used to control the symptoms of schizophrenia. The MHRA successfully seized 40,000 packs before they were distributed to pharmacies but 25,000 reached chemists acros...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...